Global Cardiac Arrest Treatment Market Size, Share, Growth Analysis Report - Forecast 2034

Cardiac Arrest Treatment Market: Industry Perspective

The global cardiac arrest treatment market size was worth around USD 5.01 Billion in 2024 and is predicted to grow to around USD 7.78 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 4.5% between 2025 and 2034. The report analyzes the global cardiac arrest treatment market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the cardiac arrest treatment industry.

Request Free Sample

Cardiac Arrest Treatment Market: Overview

Cardiac arrest is a situation wherein the heart stops beating suddenly. This occurs when the demand for oxygen towards the heart does not meet the requirement and results in the mortality of heart muscle cells causing a heart attack. Besides, there are several other reasons causing cardiac arrest like cardiomyopathy, coronary artery disease, Brugada syndrome, and long QT syndrome. Among these, coronary artery disease is the most common cause of sudden cardiac arrest especially among people above 35 years age group. The Brugada syndrome and long QT syndrome cause abnormal heart rate which develops a cardiac arrest problem within the body. The cardiomyopathy situation causes the heart muscle to develop to an abnormal size and causes cardiac arrest problems.

Key Insights

• As per the analysis shared by our research analyst, the global cardiac arrest treatment market is estimated to grow annually at a CAGR of around 4.5% over the forecast period (2025-2034).
• Regarding revenue, the global cardiac arrest treatment market size was valued at around USD 5.01 Billion in 2024 and is projected to reach USD 7.78 Billion by 2034.
• The cardiac arrest treatment market is projected to grow at a significant rate due to increasing prevalence of cardiovascular diseases, an aging population, advancements in medical technology, and rising healthcare investments.
• Based on Treatment, the Drugs segment is expected to lead the global market.
• On the basis of Distribution Channel, the Hospitals segment is growing at a high rate and will continue to dominate the global market.
• Based on region, North America is predicted to dominate the global market during the forecast period.

Cardiac Arrest Treatment Market: Growth Factors

Surge in heart ailments to boost the expansion of the global market over 2023-2030

Increase in cardiovascular disorders caused due to sedentary & inactive lifestyles with sitting jobs will boost the global cardiac arrest treatment market trends. For instance, as per the research study published in 2021, the most common heart disorder witnessed in the patients is atrial fibrillation which is a major risk factor causing ischemic stroke. This has resulted in huge morbidity in patients and incurred a high economic burden on the healthcare sector of various emerging economies, thereby increasing the demand for treating cardiovascular disorders. An increase in the aging populace and a surge in investments in R&D associated with heart diseases are the major factors driving the expansion of the global market. Increase in research on treating cardiac arrests will further enlarge the scope of the growth of the global market. New drug launches will further increase the global market demand. For instance, in the first half of 2022, Rapid Response Revival Research Limited, a key Australian firm, produced CellAED in the UK.

Cardiac Arrest Treatment Market: Restraints

Massive treatment charges for heart ailments will put brakes on the global industry

High costs of treating heart disorders and less availability of healthcare experts in emerging economies will put brakes on the global cardiac arrest treatment industry surge.

Cardiac Arrest Treatment Market: Opportunities

Supportive government reimbursement policies can create new growth avenues for the global market

Favorable government compensation policies will open new growth opportunities for the global cardiac arrest treatment market in the years ahead.

Cardiac Arrest Treatment Market: Challenges

High drug costs can create huge challenges in the growth path of the global industry

 Huge costs of medicines and strict laws pertaining to the approval of cardiac equipment will restrict the growth of the cardiac arrest treatment industry across the globe.

Cardiac Arrest Treatment Market: Segmentation

The global cardiac arrest treatment market is sectored into treatment, distribution channel, and region.        

In treatment terms, the global cardiac arrest treatment market is segregated drugs and medical devices segments. Furthermore, the medical devices segment, which accumulated nearly half of the global market revenue share in 2022, is anticipated to register the highest CAGR in the upcoming years. The growth of the segment in the assessment timeline can be owing to the growing use of defibrillators for restoring the normal heartbeat as it can send electric impulses to the heart. Moreover, these medical devices are utilized for preventing arrhythmia.

Based on the distribution channel, the cardiac arrest treatment industry across the globe is divided into hospitals, pharmacies, and others segments. Moreover, the hospitals segment, which accumulated nearly 47% of the global industry revenue share in 2022, is projected to lead the distribution channel segment in the upcoming years. The growth of the segment in the assessment timeline can be due to a rise in the number of surgeries performed in hospitals & clinics that results in huge demand for medical equipment in hospitals.  

Cardiac Arrest Treatment Market: Report Scope

Cardiac Arrest Treatment Market: Regional Insights

North America is projected to maintain global market dominance over the assessment timeline

North America, which contributed about 45% of the global cardiac arrest treatment market revenue in 2022, is predicted to lead the global market revenue in the ensuing years. The growth of the market in the region can be attributed to the rise in the rate of heart ailments witnessed in the adult population and the aging population in countries such as the U.S. and Canada. Presence of key players in these countries will drive the expansion of the market in the region.

Asia-Pacific cardiac arrest treatment industry is set to register the fastest CAGR in the upcoming years owing to a rise in the cases of heart disorders in densely populated countries such as India and China. Apart from this, a prominent rise in the use of medicines and medical equipment used for treating cardiac ailments will further embellish the growth of the market in the sub-continent.

Cardiac Arrest Treatment Market: Competitive Analysis

The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the cardiac arrest treatment market on a global and regional basis.

The global cardiac arrest treatment market is dominated by players like:

• Pfizer Inc.
• GE Healthcare
• Novartis AG
• Bayer AG
• Boston Scientific Corporation
• Amgen Inc.
• Abbott Laboratories

The global cardiac arrest treatment market is segmented as follows;

By Treatment

• Drugs
• Medical devices

By Distribution Channel

• Hospitals
• Pharmacies
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America